摘要
射血分数保留的心力衰竭(HF-PEF)是一种临床相对常见的,但预后不良的综合征。针对它的病理生理机制和治疗还有许多不明之处,因此对它的最佳治疗依然是一个医学难题。肾素-血管紧张素系统阻滞剂效益的缺乏更是对以往HF-PEF的病理生理理解提出了质疑。最近关于盐皮质激素受体拮抗剂、晚期糖基化终末产物交联破坏物、钙循环调节剂等的治疗试验,为HF-PEF治疗新策略提供了新的前景。
Heart failure with a preserved ejection fraction（ HF-PEF） is a relatively common syndrome but with a poor prognosis. There are still significant uncertainties about its pathophysiology and treatment,leaving it a clinical difficulty regarding its optimal regimen. In particular,the lack of benefit of renin-angiotensin system blockers has raised questions about the former understanding of the pathophysiology of HF-PEF. Recent trials using a mineralocorticoid receptor antagonist,advanced glycation end products crosslink breaker,calcium-cycling modulator provide important insight for the development of new therapeutic strategies for HF-PEF.
出处
《医学综述》
2016年第7期1309-1312,共4页
Medical Recapitulate
关键词
心力衰竭
射血分数保留
药物治疗
Heart failure
Preserved ejection fraction
Medical treatment
